Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG

J. C. Britell; D. L. Ahmann; H. F. Bisel; S. Frytak; J. N. Ingle; J. Rubin; J. R. O'Fallon

Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG

J. C. Britell, D. L. Ahmann, H. F. Bisel, S. Frytak, J. N. Ingle, J. Rubin, J. R. O'Fallon

Medical Oncology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.

Original language	English (US)
Pages (from-to)	345-350
Number of pages	6
Journal	Cancer clinical trials
Volume	2
Issue number	4
State	Published - 1979

ASJC Scopus subject areas

General Medicine

Cite this

@article{bab106c2c6654e73840744c92e7883e1,

title = "Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG",

abstract = "The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.",

author = "Britell, {J. C.} and Ahmann, {D. L.} and Bisel, {H. F.} and S. Frytak and Ingle, {J. N.} and J. Rubin and O'Fallon, {J. R.}",

year = "1979",

language = "English (US)",

volume = "2",

pages = "345--350",

journal = "Cancer clinical trials",

issn = "0190-1206",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG

AU - Britell, J. C.

AU - Ahmann, D. L.

AU - Bisel, H. F.

AU - Frytak, S.

AU - Ingle, J. N.

AU - Rubin, J.

AU - O'Fallon, J. R.

PY - 1979

Y1 - 1979

N2 - The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.

AB - The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.

UR - http://www.scopus.com/inward/record.url?scp=0018768740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018768740&partnerID=8YFLogxK

M3 - Article

C2 - 394870

AN - SCOPUS:0018768740

SN - 0190-1206

VL - 2

SP - 345

EP - 350

JO - Cancer clinical trials

JF - Cancer clinical trials

IS - 4

ER -

Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this